U.S. panel backs claim Lilly diabetes drug cuts cardiac death
(Reuters) - Eli Lilly & Co and Boehringer Ingelheim should be allowed to claim that their diabetes drug Jardiance cuts the risk of cardiovascular death, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - June 28, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
How Is Empagliflozin Working in Type 2 Diabetes in EMPA-REG?How Is Empagliflozin Working in Type 2 Diabetes in EMPA-REG?
Theories abound as to the mechanisms by which empagliflozin is reducing cardiovascular death and renal events in the EMPA-REG OUTCOME study; some of these were outlined at the recent ADA conference. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 28, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 27, 2016 Category: Research Source Type: news
FDA Advisory Committee recommends approval of Jardiance ® (empagliflozin) for cardiovascular indication in 12-11 vote
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 27, 2016 Category: Research Source Type: news
Empagliflozin May Be Poised To Gain CV Indication
(MedPage Today) -- FDA reviewers have raised no major questions ahead of Tuesday's advisory panel meeting (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 25, 2016 Category: Cardiology Source Type: news
Empagliflozin surpasses glimepiride as metformin add-on
NEW ORLEANS – When used as an add-on therapy to metformin in patients with type 2 diabetes mellitus, empagliflozin has sustained safety and efficacy in reducing in hemoglobin A1c... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 24, 2016 Category: Endocrinology Source Type: news
Are Expensive Diabetes Drugs Worth It?
(MedPage Today) -- Jardiance and Victoza improve hard outcomes, but at a hefty cost (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 23, 2016 Category: American Health Source Type: news
Empagliflozin slows renal disease progression in type 2 diabetes
Empagliflozin was associated with a significant 39% decrease in risk of new or worsening nephropathy, compared with placebo among adults with type 2 diabetes at high risk for cardiovascular events,... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 18, 2016 Category: Endocrinology Source Type: news
Empagliflozin offers long-term renal protection in Type 2 diabetes
The sodium–glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of the EMPA-REG OUTCOME trial. (Source: MedWire News)
Source: MedWire News - June 15, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news
Empagliflozin Slows Progression of Renal Disease in Diabetes Empagliflozin Slows Progression of Renal Disease in Diabetes
The long-awaited renal outcomes from the EMPA-REG trial with the SGLT-2 inhibitor for type 2 diabetes, empagliflozin indicate that the drug slows progression to kidney disease. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 14, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Diabetes Drug Empagliflozin May Slow Kidney Disease Progression (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The diabetes drug empagliflozin — a selective sodium-glucose cotransporter 2 inhibitor — may help slow progression of kidney disease in patients at high cardiovascular risk, according to a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 14, 2016 Category: Primary Care Source Type: news
FDA Strengthens SGLT-2 Kidney Risk Warnings
(MedPage Today) -- But no warning for Jardiance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 14, 2016 Category: American Health Source Type: news
Lilly's Jardiance slows kidney disease progression in diabetics
(Reuters) - Eli Lilly and Co's Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial that had already proved the medication's ability to greatly reduce cardiovascular deaths and hospitalizations for heart failure. (Source: Reuters: Health)
Source: Reuters: Health - June 14, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 13, 2016 Category: Research Source Type: news
Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 13, 2016 Category: Research Source Type: news
